Suppr超能文献

人卵巢腺癌的定量核DNA分析:化疗前后比较及与临床反应的相关性

Quantitative nuclear DNA analysis of human ovarian adenocarcinoma: compared before and after chemotherapy and correlated with clinical response.

作者信息

Dobashi K, Stratton J A, Teplitz R L, Liao S Y, Braly P S, Disaia P J

出版信息

Gynecol Oncol. 1986 May;24(1):81-90. doi: 10.1016/0090-8258(86)90010-7.

Abstract

Quantitative DNA measurements on 18 human ovarian adenocarcinomas were made by computerized image analysis. The DNA content of the tumor cells was measured on specimens of tumor obtained at the initial diagnostic surgery and at second-look surgery after treatment with chemotherapy. The mean DNA content of the specimens and the ploidy pattern of the tumor cells were determined. With the exception that borderline tumors had near normal ploidy patterns and mean DNA content, there was no consistent correlation between the stage of disease, grade, or histiologic character of the tumor and either the DNA content or ploidy pattern. But it was noteworthy that all three of the patients who had complete responses (negative second-looks), also had tumors with DNA content and ploidy patterns near triploid. When the ratio of mean DNA content before and after chemotherapy was determined for each ploidy group, there was an apparent correlation between this ratio and clinical status of the patient 10 month after chemotherapy. That is, patients with low ploidy tumors and high DNA content ratio (greater than 1.25) had a better prognosis than patients with high ploidy tumors and lower DNA content ratios (less than 1.25). Thus, although the mean DNA content of the tumor at the initial surgery was not in itself of sufficient prognostic value, when the mean DNA content of the tumor after chemotherapy is also known, an accurate picture of the patients clinical response could be determined.

摘要

通过计算机图像分析对18例人类卵巢腺癌进行了DNA定量检测。在初次诊断手术时以及化疗后二次探查手术时获取的肿瘤标本上测量肿瘤细胞的DNA含量。确定了标本的平均DNA含量以及肿瘤细胞的倍体模式。除了交界性肿瘤具有接近正常的倍体模式和平均DNA含量外,疾病分期、肿瘤分级或组织学特征与DNA含量或倍体模式之间没有一致的相关性。但值得注意的是,所有三名完全缓解(二次探查为阴性)的患者,其肿瘤的DNA含量和倍体模式也接近三倍体。当为每个倍体组确定化疗前后平均DNA含量的比值时,该比值与化疗后10个月患者的临床状态之间存在明显的相关性。也就是说,低倍体肿瘤且DNA含量比值高(大于1.25)的患者比高倍体肿瘤且DNA含量比值低(小于1.25)的患者预后更好。因此,虽然初次手术时肿瘤的平均DNA含量本身没有足够的预后价值,但当也知道化疗后肿瘤的平均DNA含量时,就可以确定患者临床反应的准确情况。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验